BioSpace News Archive

The U.S. Food and Drug Administration rejected Allergan’s New Drug Application for (ulipristal acetate).

Madison, Wisconsin-based EXACT Sciences stocks climbed as much as 21 percent in premarket trading in response to a deal with Pfizer to co-market Exact’s Cologuard non-invasive colon cancer test.

Football has received a lot of attention due to the significant number of players who have suffered repeated concussions. California-based Therapeutics Solutions International, Inc. (TSOI) has turned to a veteran player to help lead the development of a concussion preventative.

According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7.3 percent of cancer deaths.

By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and no one was willing to pay for it?

Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.

Months after partnering with Sanofi on infectious diseases, Germany-based Evotec has formed another significant partnership with Novo Nordisk. The two companies will combine their forces to develop treatments for diabetes, nonalcoholic steatohepatitis (NASH) and other diseases.

Shares of Tonix Pharmaceuticals shot up 25 percent in premarket trading this morning after the company announced there may be a future for its late-stage posttraumatic stress disorder treatment Tonmya after a Phase III trial was halted early in July following a data review showed an inadequate response.

Chicago-based AbbVie has exercised its exclusive license option to develop and commercialize Belgium-based Argenx’s ARGX-115. The compound is an antibody that targets novel immuno-oncology target glycoprotein A repetitions predominant (GARP).

Oxervate is the first-ever application of a human nerve growth factor as drug or treatment, and is the first-ever topical biologic medication approved in ophthalmology.